Clinical Trials

Phase 1/2 Active not recruiting

Solid Tumors

NCT03126630 2026-04-01

Pembrolizumab With or Without Anetumab Ravtansine in Treating Patients With Mesothelin-Positive Pleural Mesothelioma

49 enrolled 20 charts

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmThoracic

Mesothelioma, Malignant

NCT04234113 2026-03-27

Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors

Phase 1 Terminated

115 enrolled 43 charts

Squamous Cell Carcinoma of Head and Neck, Anus Neoplasms, Biliary Tract Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Melanoma, Mesothelioma, Ovarian Neoplasms, Stomach Neoplasms, Thymus Neoplasms, Thyroid Neoplasms, Carcinoma, Merkel Cell, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT05763004 2026-03-27

A Clinical Study to Evaluate the Safety, Tolerability and Efficacy of IOS-1002 Administered Alone and in Combination With Pembrolizumab, a PD-1 Monoclonal Antibody in Advanced Solid Tumors

140 enrolled

Solid Tumor, Adult

NCT06462794 2026-03-24

First In Human Study of CX-801 in Advanced Solid Tumors

121 enrolled

Solid Tumor, Adult

NCT07182591 2026-03-20

A Study of DS5361b in Participants With Advanced Solid Tumors

192 enrolled

Advanced Solid Tumor

NCT05101070 2026-03-18

aCCeleR8-001

282 enrolled

Phase 1/2 Not yet recruiting

Solid Tumors

NCT07469774 2026-03-13

BC3195 in Combination With Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors

111 enrolled

Locally Advanced or Metastatic Solid Tumors

NCT04897022 2026-03-12

A Study of Pembrolizumab and Radiation Therapy in People With Mesothelioma

7 enrolled

Mesothelioma, Malignant

NCT06234397 2026-03-11

Dose Escalation and Expansion Study of BH3120 Alone or With Pembrolizuamb in Advanced or Metastatic Solid Tumors

245 enrolled

Advanced or Metastatic Solid Tumors

NCT02959463 2026-03-06

Pembrolizumab After Radiation Therapy in Treating Patients With Pleural Malignant Mesothelioma

24 enrolled 11 charts

Phase 1/2 Active not recruiting

Mesothelioma, Malignant

NCT04262466 2026-03-06

Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors

410 enrolled

Select Advanced Solid Tumors

NCT06795412 2026-03-06

Phase 1/2 Study of PYX-201 in Combination With Pembrolizumab in Advanced Solid Tumors

220 enrolled

Advanced Solid Tumours

NCT03313778 2026-03-04

KEYNOTE-603

161 enrolled

Solid Tumors

NCT06994806 2026-03-03

A Study to Investigate the Safety and Efficacy of KQB168 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies

84 enrolled

Solid Tumor Malignancies

NCT07098988 2026-02-27

Trial Investigating Visugromab in Combination With Immunochemotherapy in 1L Treatment of Participants With Metastatic NSCLC

Phase 2 Recruiting

107 enrolled

Metastatic Non-Squamous Non-Small Cell Lung Cancer

NCT05067283 2026-02-12

KANDLELIT-001

830 enrolled

Advanced Solid Tumors

NCT05701527 2026-02-05

A Study of EBC-129 in Advanced Solid Tumours

98 enrolled

Advanced Solid Tumours

NCT04166734 2026-02-04

MESO-PRIME

Phase 1 Terminated

5 enrolled 13 charts

Mesothelioma

NCT07215637 2026-02-02

Phase Ia/Ib Study of CKD-512 Alone and in Combination With Pembrolizumab in Subjects With Advanced or Metastatic Solid Tumors

60 enrolled

BreastGastrointestinalGenitourinaryHead & NeckOther solid neoplasmThoracic

Advanced Solid Tumors

NCT05070247 2026-01-22

A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors

Phase 1/2 Terminated

61 enrolled 29 charts

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Kidney Neoplasms, Liver Neoplasms, Mesothelioma, Nasopharyngeal Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms

NCT02856425 2026-01-20

PEMBIB

Phase 1 Completed

196 enrolled

GastrointestinalOther solid neoplasm

Patients With Any Advanced Solid Tumors

NCT06006923 2026-01-20

Regorafenib in Combination With Pembrolizumab or Pembrolizumab for MSI-H Colorectal Cancer

Phase 2 Terminated

1 enrolled

MSI-H Colorectal Cancer

NCT06302426 2026-01-16

Trial of INI-4001 in Patients With Advanced Solid Tumours

50 enrolled

Advanced Solid Tumor

NCT06932952 2026-01-16

A Dose Escalation and Expansion Trial With BYON4228 Alone and in Combination in Patients With Advanced or Metastatic Solid Tumors

7 enrolled

Solid Tumor

NCT07231458 2026-01-16

A Study to Test a New Immunotherapy, ABX-001, Alone and in Combination With the Marketed Drug, Pembrolizumab, for the Treatment of Tumors Previously Treated With Other Therapies

27 enrolled

Phase 2 Active not recruiting

Advanced Solid Tumors

NCT06155279 2026-01-13

CHIMERA

41 enrolled

Mesothelioma, Malignant

NCT05405595 2026-01-07

ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors

186 enrolled

Advanced/Metastatic Solid Tumors

NCT05174585 2026-01-06

JAB-BX102 Monotherapy and Combination With Pembrolizumab in Adult Patients With Advanced Solid Tumors

Phase 1/2 Completed

21 enrolled

Solid Tumor

NCT05544929 2026-01-06

A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmThoracic

126 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Ovarian Epithelial, Nasopharyngeal Carcinoma, Anus Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Colonic Neoplasms, Esophageal Neoplasms, Head and Neck Neoplasms, Intestinal Neoplasms, Kidney Neoplasms, Lung Neoplasms, Melanoma, Mesothelioma, Nasopharyngeal Neoplasms, Neoplasms, Ovarian Neoplasms, Rectal Neoplasms, Skin Neoplasms, Thymoma, Thymus Neoplasms, Colorectal Neoplasms, Adenocarcinoma, Clear Cell, Triple Negative Breast Neoplasms

NCT06391775 2025-12-26

Trial to Assess the Safety and Preliminary Efficacy of GEN1055 on Malignant Solid Tumors as Monotherapy and as Combination Therapy

Phase 1/2 Terminated

21 enrolled

Malignant Solid Tumor

NCT05307874 2025-12-24

EVICTION-2

Phase 1/2 Completed

56 enrolled

Solid Tumor, Adult

NCT06328673 2025-12-24

A Study of DM919 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors

160 enrolled

Advanced Solid Tumor

NCT06724016 2025-12-17

Dose Escalation and Expansion Study of HM16390 Alone or With Pembrolizumab in Advanced or Metastatic Solid Tumors

292 enrolled

Advanced or Metastatic Solid Tumors

NCT03556228 2025-12-11

VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma

GastrointestinalHead & NeckOther solid neoplasmThoracic

242 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Adenoid Cystic, Esophageal Neoplasms, Head and Neck Neoplasms, Laryngeal Diseases, Lung Neoplasms, Mesothelioma, Neoplasm Metastasis, Pancreatic Neoplasms, Salivary Gland Neoplasms, Tracheal Diseases, Small Cell Lung Carcinoma

NCT04381650 2025-12-10

A Study of TAK-981 Given With Pembrolizumab in Participants With Select Advanced or Metastatic Solid Tumors

Phase 1/2 Completed

161 enrolled 44 charts

Advanced or Metastatic Solid Tumors

NCT07174453 2025-12-08

Trial to Evaluate irAEs With Different Standard of Care Dosing Strategies of Standard of Care Immunotherapies

Phase 3 Recruiting

192 enrolled